Dapagliflozin (DAPA), a sodium–glucose linked transporter 2 (SGLT-2) inhibitor, was originally developed to regulate blood glucose levels in patients with type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.